ATE298578T1 - Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung - Google Patents

Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung

Info

Publication number
ATE298578T1
ATE298578T1 AT97929518T AT97929518T ATE298578T1 AT E298578 T1 ATE298578 T1 AT E298578T1 AT 97929518 T AT97929518 T AT 97929518T AT 97929518 T AT97929518 T AT 97929518T AT E298578 T1 ATE298578 T1 AT E298578T1
Authority
AT
Austria
Prior art keywords
analogues
production
containing lipid
injections containing
lipid
Prior art date
Application number
AT97929518T
Other languages
English (en)
Inventor
Yasuyuki Asai
Katsumi Onai
Kazuhide Ashizawa
Kiyoshi Iwamoto
Yasuo Ishibashi
Sumio Watanabe
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE298578T1 publication Critical patent/ATE298578T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97929518T 1996-07-03 1997-07-03 Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung ATE298578T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17361596 1996-07-03
PCT/JP1997/002316 WO1998001139A1 (fr) 1996-07-03 1997-07-03 Produits pour injection contenant des analogues de lipides a et procede de preparation correspondant

Publications (1)

Publication Number Publication Date
ATE298578T1 true ATE298578T1 (de) 2005-07-15

Family

ID=15963903

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929518T ATE298578T1 (de) 1996-07-03 1997-07-03 Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung

Country Status (9)

Country Link
US (1) US6235724B1 (de)
EP (1) EP0909562B1 (de)
CN (1) CN1150001C (de)
AT (1) ATE298578T1 (de)
CA (1) CA2259520C (de)
DE (1) DE69733651T2 (de)
DK (1) DK0909562T3 (de)
ES (1) ES2242226T3 (de)
WO (1) WO1998001139A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501540A (ja) * 1997-05-23 2002-01-15 エーザイ株式会社 製薬製剤を調製するための方法
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
CA2333578C (en) * 1998-07-14 2010-11-16 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6906042B2 (en) * 2000-02-18 2005-06-14 Eisai Co., Ltd. Micelles
ATE534401T1 (de) 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
WO2002094019A1 (en) * 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
EP2468300B1 (de) 2006-09-26 2017-12-20 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (de) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Verfahren und zusammensetzungen für therapeutika
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
EP3678695A1 (de) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomale formulierungen enthaltend saponin und verwendungsverfahren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216686B (it) 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
JPH04198192A (ja) * 1990-11-28 1992-07-17 Japan Tobacco Inc リピッドa類縁体の水溶液
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Also Published As

Publication number Publication date
EP0909562B1 (de) 2005-06-29
DE69733651D1 (de) 2005-08-04
CN1150001C (zh) 2004-05-19
DK0909562T3 (da) 2005-08-22
EP0909562A1 (de) 1999-04-21
EP0909562A4 (de) 1999-12-29
CN1224355A (zh) 1999-07-28
WO1998001139A1 (fr) 1998-01-15
CA2259520A1 (en) 1998-01-15
CA2259520C (en) 2007-09-11
ES2242226T3 (es) 2005-11-01
US6235724B1 (en) 2001-05-22
DE69733651T2 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
DE69733651D1 (de) Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung
DE68904986D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichlorethan.
DE68923805D1 (de) Verfahren zur herstellung von optisch aktivem 1,3-butanediol.
DE3876557D1 (de) Verfahren zur herstellung waessriger polymerdispersionen.
DE68907057D1 (de) Naehrstoffzusammensetzung und verfahren zu deren herstellung.
DE59000326D1 (de) Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten.
DE69107949D1 (de) MOS-gesteuerter Thyristor und Verfahren zu dessen Herstellung.
DE3785163D1 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeurederivate und verfahren zu deren herstellung.
ATE293595T1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
DE3786097D1 (de) Polysiloxazane, silikonoxynitrid-fasern und verfahren zu deren herstellung.
DE3862937D1 (de) 3-oxo-propannitril heteroarylderivate und verfahren zu deren herstellung.
DE3772590D1 (de) Verfahren zur herstellung von 1,4-dihydropyridin-derivaten.
DE3862019D1 (de) Homogene, mehrfarbig strukturierte kunststoffbahn oder -platte sowie verfahren zu deren herstellung.
DE68902670D1 (de) Ks-506 verbindungen und verfahren zu deren herstellung.
DE3777122D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE59001106D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan.
DE68912809D1 (de) Verfahren zur Herstellung von Bis(2,2,6,6-tetramethyl-4-piperidyl)amin.
DE68906500D1 (de) Verfahren zur herstellung von 2,6-dimethylnaphthalin.
DE68906372D1 (de) Verfahren zur herstellung von optisch aktiven threo-dihydroxyphenylserine-derivaten.
DE3869633D1 (de) Verfahren zur herstellung von n,n-(dibenzohexatrienylen)harnstoffen.
DE68907180D1 (de) Verfahren zur herstellung von 2,3,5-trimethylbenzochinon.
DE69130215D1 (de) Verfahren zur herstellung von hexahydropyridazin-1,2-dicarbonsäurederivaten
ATE128113T1 (de) Calicheamicinon, dessen abkömmlinge und analogen und verfahren zu deren herstellung.
DE68901576D1 (de) Verfahren zur herstellung von 2,3,5-trimethylbenzochinon.
DE3861897D1 (de) Verfahren zur herstellung von 4-hydroxy-2,2,6,6-tetramethyl-piperidin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0909562

Country of ref document: EP

EEIH Change in the person of patent owner